# Proof of Concept: Effects of an Immune-Enhancing Formula on Clinical Markers of Critical Coronavirus Disease 2019 Cases

**Authors:** Yi-Cheng Hou, Su-Ting Lin, Chin-Hsuan Yang, Kuo-Wang Tsai, Jing-Huei Wu, Hsiang-Yu Huang, Wen-Lin Su

PMC · DOI: 10.3390/biomedicines13020309 · Biomedicines · 2025-01-27

## TL;DR

This study explores whether an immune-enhancing formula with arginine and glutamine can improve clinical outcomes in severe COVID-19 patients.

## Contribution

It presents a novel application of immune-enhancing enteral formulas in critical COVID-19 care.

## Key findings

- An increase in IL-10 levels was observed in patients receiving the immune-enhancing formula.
- Other inflammatory cytokine levels showed no significant changes.
- The study suggests potential benefits of the formula on anti-inflammatory markers.

## Abstract

Background/Objectives: The rapid viral spread observed in coronavirus disease 2019 (COVID-19) is capable of inducing the secretion of excessive inflammatory cytokines. The resulting multi-organ damage is a severe complication that can be attenuated through adequate nutrition. Formulae enhanced with either glutamine or arginine are conditionally essential amino acids that have been proven to improve the condition of hospitalized patients. This retrospective study aimed to investigate the effects of administering an immune-enhancing enteral formula enhanced with arginine and glutamine on the clinical signs and biomarkers of patients with severe COVID-19. Methods: After checking the data of 232 patients enrolled in the biobank for completeness and eligibility, 31 patients with severe COVID-19 in the intensive care unit at Taipei Tzu Chi Hospital were grouped based on the type of enteral formula used: 16 patients received the control formula, and 15 patients received the immune-enhancing formula. Baseline characteristics, clinical signs, and inflammatory markers were analyzed for differences. Results: An increase in IL-10 levels in the intervention group was observed (p = 0.048). Changes in other inflammatory cytokine levels were insignificant. Conclusions: Providing an enteral formula enriched with glutamine and arginine to severe COVID-19 patients may help improve their anti-inflammatory marker levels. Further interventional study utilizing enteral formula enriched with glutamine and arginine is needed to confirm the findings of this study.

## Linked entities

- **Chemicals:** arginine (PubChem CID 232), glutamine (PubChem CID 738), IL-10 (PubChem CID 146070)
- **Diseases:** coronavirus disease 2019 (MONDO:0100096), COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** inflammatory (MESH:D007249), multi-organ damage (MESH:D000092124), COVID-19 (MESH:D000086382), inflammatory cytokines (MESH:D000080424), Critical (MESH:D016638)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11852627/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11852627/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC11852627/full.md

---
Source: https://tomesphere.com/paper/PMC11852627